Myeloid-specific Tristetraprolin mitigates postsurgical incisional pain by suppressing proinflammatory responses

Abhishek Guha1,2,3, Robert E Sorge4, Ying Si1,2,3

  • 1Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA, 35294.

Research Square
|November 24, 2025
PubMed
Abstract

Insights

Tristetraprolin (TTP) suppresses postsurgical pain by reducing inflammation. Deleting TTP worsened pain and inflammation, while increasing TTP reduced it, highlighting TTP as a therapeutic target.

Area of Science:

  • Immunology
  • Neuroscience
  • Molecular Biology

Background:

  • Proinflammatory mediators (COX-2, IL-1β, IL-6, TNF-α) initiate postsurgical pain.
  • These mediators are regulated post-transcriptionally via adenine- and uridine-rich elements (ARE) in mRNA.
  • Tristetraprolin (TTP), an ARE-binding protein, degrades mRNA and silences translation of these mediators.

Purpose of the Study:

  • To investigate the role of TTP in postsurgical pain.
  • To determine TTP's impact on inflammatory responses in a mouse model.

Main Methods:

  • Mice with myeloid-specific TTP knockout or knock-in were subjected to paw incision.
  • Mechanical allodynia and thermal sensitivity were assessed.
  • Inflammatory responses were monitored in skin, dorsal root ganglia (DRG), and spinal cord (L-SC).

Main Results:

  • TTP deletion exacerbated incisional pain, increased edema, and delayed wound healing.
  • TTP deletion led to increased macrophages and proinflammatory mediators at the injury site and systemically.
  • TTP knock-in attenuated pain and inflammatory responses.

Conclusions:

  • TTP is critical for mitigating postsurgical pain.
  • TTP suppresses peripheral, central, and systemic inflammatory responses.
  • TTP represents a potential therapeutic target for pain management.

Related Concept Videos